Aptevo Therapeutics Inc Dossier - Source-backed chat

Aptevo Therapeutics Inc

APVONASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.43

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $1.82Price as of 30 Sep 2026

Data confidenceNot applicable

Market Cap $3.3M

Enterprise Value −$18.3M

Shares Outstanding 1.8M diluted

Next Earnings Date9 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Aptevo Therapeutics is a clinical-stage biotechnology company positioned at a pivotal inflection point. The company's lead clinical candidate, mipletamig (a CD123 x CD3 bispecific T-cell engager), has demonstrated highly compelling clinical efficacy in frontline acute myeloid leukemia (AML) in combination with venetoclax and azacitidine. In its ongoing Phase 1b/2 RAINIER trial, mipletamig achieved an 87% clinical benefit rate and an 81% CR/CRi rate across 31 evaluable patients, substantially outperforming historical benchmarks. Crucially, no cytokine release syndrome (CRS) has been observed in frontline patients, highlighting a highly differentiated safety profile. Backed by a newly secured $60 million Standby Equity Purchase Agreement (SEPA) extending capital access into 2029, and a refreshed executive leadership team under CEO Jeff Lamothe, Aptevo is well-positioned to achieve its upcoming clinical milestones, including Phase 2 dose selection by year-end 2026.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets2 analysts · as of 18 Aug 2026

Low · most bearish analyst$21.00

Mean target$25.50

High · most bullish analyst$30.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

The bear case reflects the high-risk nature of micro-cap clinical-stage biotech companies. If the RAINIER trial experiences enrollment delays or unexpected safety signals emerge in larger patient cohorts, the timeline to Phase 2 will be pushed back. Furthermore, heavy reliance on the $60 million SEPA facility could lead to severe share dilution, depressing the stock price. If the company fails to maintain Nasdaq's minimum stockholders' equity requirement, it could face delisting, driving the stock toward historical lows.

Base CaseCentral scenario

The base case assumes that the RAINIER trial successfully completes by year-end 2026, leading to the selection of the Phase 2 dose for mipletamig. The clinical data continues to show superior efficacy and safety compared to standard-of-care benchmarks. The company utilizes its $60 million SEPA facility opportunistically to fund operations without causing excessive dilution, and successfully maintains its Nasdaq listing. An independent small-cap research firm initiated coverage with a $30.00 valuation based on a probability-adjusted DCF model, which serves as our primary target.

Bull CaseUpside scenario

Trading at a deep discount to book value (0.24x to 0.5x) with a negative enterprise value, meaning its cash balance exceeds its market capitalization. Any positive clinical data from its pipeline (such as mipletamig in acute myeloid leukemia or ALG.APV-527 in solid tumors) or strategic partnerships could create highly asymmetric upside from a very low valuation base.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Compelling clinical data for lead candidate mipletamig in frontline AML, showing an 87% clinical benefit rate and 81% CR/CRi rate, outperforming standard-of-care benchmarks.
Differentiated safety profile with zero cytokine release syndrome (CRS) observed in frontline patients to date.
Refreshed leadership team with Jeff Lamothe appointed as CEO and Marvin White transitioning to Executive Chair to focus on strategic opportunities.
Enhanced financial flexibility through a newly secured $60 million Standby Equity Purchase Agreement (SEPA) extending capital access into 2029.
Expansion of the pipeline into high-value modalities, including a strategic collaboration with Niowave for radiopharmaceutical therapeutic development.

Key Investment Risks

High reliance on dilutive equity financing (such as the SEPA facility) to fund ongoing clinical trials in the absence of product revenue.
Risk of clinical trial delays, failure to meet primary endpoints, or emergence of adverse safety profiles in larger patient cohorts.
Nasdaq listing compliance risk due to historical stockholders' equity deficits below the minimum $2.5 million requirement.
Extreme stock price volatility and historical downward pressure, including multiple reverse stock splits.

Thesis Invalidation Triggers

Failure to select the Phase 2 dose or complete the RAINIER trial by year-end 2026.
Occurrence of severe adverse events, such as high-grade cytokine release syndrome (CRS), in frontline mipletamig patients.
Inability to maintain Nasdaq listing requirements leading to delisting to over-the-counter (OTC) markets.
Excessive share dilution from SEPA drawdowns that severely erodes shareholder value without corresponding clinical progress.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.